Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 10/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30204313 | 0.91 | ALDH1A1 (0.38) | ALDH1A1PTGER4CSNK2A1 | |
| SCHEMBL30864255 | 0.82 | HCAR3 (0.38) | HCAR3ALDH1A1PTGER4TNKSTNKS2 | |
| SCHEMBL30159550 | 0.82 | HCAR3 (0.36) | HCAR3TNKSTNKS2SLC22A12CSNK2A1 | |
| SCHEMBL23535658 | 0.82 | HCAR3 (0.36) | HCAR3TNKSTNKS2SLC22A12CSNK2A1 | |
| SCHEMBL1242165 | 0.74 | F2 (0.41) | HCAR3ALDH1A1 | |
| SCHEMBL30159691 | 0.73 | NOTUM (0.40) | ALDH1A1 | |
| SCHEMBL23535765 | 0.73 | NOTUM (0.40) | ALDH1A1 | |
| SCHEMBL2497481 | 0.72 | F2 (0.45) | ALDH1A1 | |
| SCHEMBL23535847 | 0.72 | HCAR3 (0.44) | HCAR3ALDH1A1SLC22A12CSNK2A1 | |
| SCHEMBL30039575 | 0.72 | HCAR3 (0.44) | HCAR3ALDH1A1SLC22A12CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | HCAR3 2931/4885ALDH1A1 1756/4885PTGER4 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.